INTRODUCTION

Major depressive disorder (MDD) is the most prevalent psychiatric disease with a highly variable treatment response to antidepressants, with up to one-third of patients not achieving an adequate response to the first-line antidepressant treatment. 

Selective serotonin reuptake inhibitors ( SSRIs ) are the first choice in the pharmacological treatment of most cases of depression and their therapeutic window has not been established. Large inter-individual variations in the pharmacokinetics and pharmacodynamics of antidepressants, requires the development of adequate tools for optimizing treatment a major aim for psychopharmacology research.

Citalopram (CITA) as a racemic drug (R, S-citalopram) is a widely used and well-tolerated antidepressant that belongs to the SSRI class. CITA is metabolized to n-desmethylcitalopram (NDCITA) and n-didesmethylcitalopram (NDDCITA) through n-demethylation. The concentrations of these metabolites at steady state in the plasma in relation to the CITA levels are 30–50% for NDCITA and 5–10% for NDDCITA. With a wide...
inter-individual variation, the plasma half-life ($t_{1/2}$) at steady state is approximately 35 hours for CITA, 50 hours for NDCITA, and 100 hours for NDDCITA. Although in vitro studies suggested that CITA is mainly responsible for the antidepressant effect, NDCITA also has affinity for the human serotonin transporter that cannot be ignored, especially at higher serum concentrations.

As for most SSRIs, the therapeutic window of CITA hasn’t been established yet. Although an earlier study recommended a 30 ng/mL steady-state serum concentration as a lower limit, two recent studies suggested that 50 ng/mL of serum CITA concentrations are required at steady state for efficient therapy. However, studies that examine the effects of serum NDCITA concentrations on the clinical response to CITA are lacking in the literature. The aim of the current study was to evaluate the possible influences of serum concentrations of CITA and NDCITA on the efficacy and tolerability of CITA in MDD patients.

METHODS

Subjects and treatment

The subjects of this study ($n=46$) were part of a previously reported study to investigate the effects of ABCB1 C3435T polymorphism on susceptibility to depression and the clinical response to CITA. The study was conducted in a prospective and open-label style between 2006 and 2008 at the Gazi University Medical Faculty Hospital, Ankara, Turkey. Patients who applied to the psychiatric outpatient clinic and met the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for MDD were included in the study. The exclusion criteria included clinically significant laboratory abnormalities; major physical and neurological illnesses; psychiatric disorders except for major depression; substance abuse and dependence, except for nicotine dependence; pregnancy; breastfeeding; using any antidepressant drug within the previous 12 months; being younger than 18 and older than 65; and treatment with concomitant psychotropic drugs, except for hydroxyzine for insomnia. All participants were biologically unrelated Turkish subjects and were recruited from the same geographical area (Ankara region of Turkey). The study was approved by the Human Ethics Committee of the Gazi University Medical Faculty Hospital, according to the 2004 Helsinki Declaration (approval number, 271; date, 25.09.2006). Patients were informed about the study and they gave their written informed consent.

CITA was administered at an initial dose of 20 mg/day, with the possibility of adjustment up to 30 mg/day according to the therapeutic response. All patients affirmed an intake of CITA once a day between 8:00 and 9:00 p.m. every day during the study. Blood samples were taken from 8:00–9:00 a.m. (12 hours after the drug administration) at the 4th week for the measurement of steady-state drug concentrations. Protocol visits were completed at baseline and at the 1st, 2nd, 4th, and 6th weeks. The therapeutic response to CITA was evaluated by psychiatrists using the 17-item Hamilton Rating Scale for Depression (HDRS17) at baseline and at the 1st, 2nd, 4th, and 6th weeks. The responders were defined as patients who demonstrated a 50% reduction from the baseline HDRS17 total score at the 6th week. Tolerability assessments were conducted based on a query of side effects (dry mouth, nausea, constipation, palpitation, dizziness, increased perspiration, itching, headache, tremor, blurred vision, difficulty sleeping, sleeping too much, loss of sexual desire, poor concentration) at the 1st, 2nd, and 6th weeks by psychiatrists.

Analytical methods

Venous blood samples were drawn (10 mL) into the tubes that did not contain any additives, were centrifuged for 10 minutes at 3000 g immediately, and serum samples were stored at -20°C.

The serum concentrations of CITA and NDCITA were analyzed by an isocratic reversed-phase high-performance liquid chromatography (HPLC) method with ultraviolet detection (Agilent LC Systems, Series 1100, Agilent Technologies Inc., Santa Clara, CA, USA) as previously described. The lowest limit of quantification was 5.0 ng/mL for both analytes. Coefficients of accuracy and precision for citalopram and NDCITA were 6.6, 92.1, 6.5, and 89.5%, respectively.

Statistical analysis

Statistical analysis focused on the comparison of three groups, which were defined according to the median CITA, NDCITA, and the sum of the CITA & NDCITA concentrations of patients. Patients with 25% above the median concentrations were defined as the “high CITA group” (>136.0 ng/mL), the “high NDCITA group” (>73.25 ng/mL), and the “high CITA & NDCITA group” (>197.5 ng/mL); those with 25% below the median concentrations were defined as the “low CITA group” (<86.0 ng/mL), the “low NDCITA group” (<42.75 ng/mL), and the “low CITA & NDCITA group” (<136.3 ng/mL); and those within the reference medians ±25% were defined as the “expected CITA group” (86.0–136.0 ng/mL), the “expected NDCITA group” (73.25–42.75 ng/mL), and the “expected CITA & NDCITA group” (136.3–197.5 ng/mL). The comparison of age, baseline HDRS17 total score, CITA dose, serum CITA, NDCITA, and CITA & NDCITA concentrations among the groups were performed by one-way ANOVA. Male/female ratios among the groups were compared by the chi-squared test. Changes in the groups’ reduction in HDRS17 total scores...
Table 1. Patient characteristics according to serum CITA, NDCITA, and CITA & NDCITA concentrations

| Patient characteristics | ng/mL | Groups according to serum concentrations |
|-------------------------|-------|------------------------------------------|
|                         |       | CITA                                     | NDCITA                                 | CITA & NDCITA                           |
|                         | Low   | Expected | High | Low   | Expected | High | Low   | Expected | High |
|                         | <86   | 86–136   | >136 | <42.8 | 42.8–73.3 | >73.3 | <136.3 | 136.3–197.5 | >197.5 |
| N                       | 46    | 11       | 22   | 13    | 11       | 24   | 11    | 24       | 11    |
| Age                     | 39.4±13.6 | (18–65; 37) | 41.7±11.6 | (30–62; 37) | 39.9±12.8 | (18–64; 37) | 36.4±16.6 | (20–65; 31) | 38.0±13.7 | (22–62; 32) | 43.0±14.4 | (18–65; 42) | 33.8±10.1 | (20–51; 35) | 38.1±13.0 | (24–62; 32) | 42.0±13.3 | (18–65; 42) | 34.8±14.6 | (20–63; 34) |
| F                      | 0.4866, p=0.6180 | F=1.663, p=0.2015 | F=1.125, p=0.3341 |
| Sex                     | 37/9 | 9/2 | 16/6 | 12/1 | 9/2 | 20/4 | 8/3 | 10/1 | 18/6 | 9/2 |
| χ²                     | 2.008, df=2, p=0.3664 | χ²=0.5567, df=2, p=0.7570 | χ²=1.231, df=2, p=0.5405 |
| HDRS₁₇b                 | 17.3±4.6 | (10–33; 17) | 17.8±5.9 | (12–33; 17) | 17.4±6.7 | (10–26; 17) | 16.3±3.6 | (12–26; 17) |
| F                      | 0.3315, p=0.7197 | F=1.097, p=0.3430 | F=0.8598, p=0.4304 |
| CITA dose               | 27.2±4.6 | (20–30; 30) | 25.5±5.2 | (20–30; 30) | 29.1±2.9 | (20–30; 30) | 25.4±5.2 | (20–30; 30) |
| F                      | 4.285, p=0.0201* | F=9.620, p=0.0004*** | F=1.122, p=0.3351 |
| Concentrations          | 69.4±12.3 | (42–83; 74) | 101.9±9.2 | (87–121; 101) | 160.5±40.5 | (136–280; 144) | 254±39.4 | (12–42; 28) |
| F                      | 49.48, p<0.0001*** | F=47.63, p<0.0001*** | F=39.84, p<0.0001*** |
| C/D ratio               | 2.8±0.7 | (2.0–4.1; 2.6) | 3.6±0.7 | (2.9–6.1; 3.4) | 6.5±1.8 | (4.5–10.2; 6.8) | 1.1±0.4 | (0.6–1.8; 1.1) |
| F                      | 39.52, p<0.0001*** | F=35.92, p<0.0001*** | F=19.33, p<0.0001*** |

Age, HDRS₁₇b, CITA dose (mg/day), serum concentrations, and concentration/dose ratios (C/D) values are expressed as mean±SD (range; median), and sex values expressed as number; one way ANOVA (analysis of variance) and chi-square test (χ²) was applied for the comparisons. *p<0.05, ***p<0.001. CITA: citalopram, NDCITA: n-desmethylcitalopram, CITA & NDCITA: citalopram and n-desmethylcitalopram, HDRS₁₇b, baseline hamilton depression rating scale 17, SD: standard deviation, NS: nonsignificant
RESULTS

Of the 54 patients included in the study, 8 patients dropped out due to the adverse effects or refusal of regular visits. Thus, 46 subjects of the 54 enrolled had sufficient data to analyze. The demographic characteristics; mean HDRS17 total scores at baseline; CITA doses (mg/day); serum CITA, NDCITA, and CITA & NDCITA concentrations (ng/mL); and CITA, NDCITA, and CITA & NDCITA concentration/dose ratios (ng/mL/mg/day) as described above are shown in Table 1. No significant differences were found among the groups according to serum concentrations of CITA, NDCITA, and CITA & NDCITA for age (F=0.4866, p=0.6180; F=1.663, p=0.2015; F=1.125, p=0.334; respectively), sex (χ²=2.008, df=2, p=0.3664; χ²=0.5567, df=2, p=0.7570; χ²=1.231, df=2, p=0.5405; respectively), and the baseline HDRS17 total scores (F=0.3315, p=0.7197; F=1.097, p=0.3430; F=0.8598, p=0.4304; respectively). However, among the three groups of patients, significant differences were found in the serum concentrations and concentrations/dose ratios of CITA (F=49.48, p<0.0001; F=39.52, p<0.0001; respectively), NDCITA (F=47.63, p<0.0001; F=35.92, p<0.0001; respectively), and CITA & NDCITA (F=39.84, p<0.0001; F=19.33, p<0.0001; respectively). Although the CITA dose was differed significantly among the groups for serum CITA concentrations (F=1.227, p=0.293) and NDCITA (F=3.717, p=0.002) and CITA & NDCITA concentrations (F=3.523, p=0.003), respectively) (Table 2).

Serum concentrations and efficacy

The efficacy of CITA was evaluated by HDRS17 total scores for patients with low, expected, and high serum CITA and NDCITA concentrations for 6 weeks. Although the HDRS17 total scores of patients did not differ significantly among the groups for serum CITA concentrations (F=1.576, p=0.152) (Table 2), patients with high NDCITA and CITA & NDCITA concentrations showed a more significant reduction in HDRS17 total scores during the 6 week than did patients with expected and low serum NDCITA and CITA & NDCITA concentrations (F=3.717, p=0.002; F=3.523, p=0.003, respectively) (Table 2).

Serum concentrations and tolerability

The tolerability of CITA was examined for patients with low, expected and high serum CITA, NDCITA, and CITA & NDCITA concentrations in reporters and non-reporters of side effects. The low, expected, and high serum concentration groups did not differ with respect to the reported side effects for CITA, NDCITA, and CITA & NDCITA concentrations (Table 3).

DISCUSSION

The present results provide the first evidence that the HDRS17 total scores of the patients with high NDCITA concentrations show a more significant reduction compared to the patients with expected and high serum NDCITA concentrations in MDD patients. However, HDRS17 total scores were not associated with serum CITA concentrations. In addition, no correlation was observed between the serum CITA and serum NDCITA concentrations and adverse reactions.

Previous studies have revealed that the steady-state concentrations of CITA predict the antidepressant response of CITA in MDD patients. Although Ostad Haji et al. suggested that achieving approximately 50 ng/mL serum concentrations for CITA on day 7 is necessary for clinical improvement, an earlier study concluded that the lower limit of effective se-

| HDRS17 scores | CITA concentrations | NDCITA concentrations | CITA & NDCITA concentrations |
|---------------|---------------------|-----------------------|-----------------------------|
|               | Low | Expected | High   | Low | Expected | High   | Low | Expected | High   |
| N             | 11  | 22       | 13     | 11  | 24       | 11     | 11  | 24       | 11     |
| HDRS17 baseline | 17.8±1.8 | 17.3±1.0 | 16.3±1.0 | 17.0±1.2 | 16.4±1.0 | 18.9±1.5 | 18.6±1.7 | 16.4±1.0 | 17.3±1.0 |
| HDRS17 1st week | 12.8±1.3 | 14.1±1.2 | 10.9±1.2 | 12.5±1.0 | 13.1±1.0 | 12.8±2.0 | 13.8±1.3 | 13.6±1.1 | 10.5±1.5 |
| HDRS17 2nd week | 8.4±1.4 | 10.4±1.5 | 8.5±1.1 | 7.0±0.9 | 9.3±1.0 | 11.9±2.5 | 8.2±1.4 | 10.7±1.3 | 7.6±1.4 |
| HDRS17 4th week | 7.3±2.0 | 6.9±1.0 | 5.4±1.2 | 6.2±0.9 | 6.2±1.2 | 7.6±1.7 | 8.5±1.8 | 6.1±1.0 | 5.5±1.4 |
| HDRS17 6th week | 6.5±1.8 | 5.2±0.9 | 4.1±1.2 | 5.3±1.1 | 5.8±1.1 | 4.0±1.5 | 7.0±1.7 | 5.0±0.9 | 4.0±1.4 |

Repeated measures analysis of variance was applied for the comparisons. *p<0.05. HDRS17: baseline hamilton depression rating scale 17, CITA: citalopram, NDCITA: n-desmethylcitalopram, CITA & NDCITA: citalopram and n-desmethylcitalopram, HDRS17: hamilton depression rating scale 17
Table 3. Side effects of patients during the study according to serum CITA, NDCITA, and CITA & NDCITA concentrations

| Side effects        | CITA | NDCITA | CITA & NDCITA |
|---------------------|------|--------|---------------|
|                     | R    | NR     | p values      | R    | NR     | p values      | R    | NR     | p values      |
| Dry mouth           |      |        |               |      |        |               |      |        |               |
| Low-expected        | 0.744| 1.000  | 1.000         | 19   | 16     | 1.000         | 19   | 16     | 1.000         |
| High                |      |        |               | 8    | 5      | 1.000         | 6    | 5      | 1.000         |
| Nause               | 0.185| 0.320  | 0.092         |      |        |               |      |        |               |
| Low-expected        | 16   | 17     | 1.000         | 16   | 19     | 1.000         | 17   | 18     | 1.000         |
| High                | 3    | 10     | 1.000         | 3    | 8      | 1.000         | 2    | 9      | 1.000         |
| Constipation        | 0.435| 1.000  | 1.000         |      |        |               |      |        |               |
| Low-expected        | 6    | 27     | 1.000         | 8    | 27     | 1.000         | 8    | 27     | 1.000         |
| High                | 4    | 9      | 1.000         | 2    | 9      | 1.000         | 2    | 9      | 1.000         |
| Palpitation         | 0.867| 1.000  | 1.000         |      |        |               |      |        |               |
| Low-expected        | 3    | 30     | 5.000         | 6    | 29     | 5.000         | 5    | 30     | 5.000         |
| High                | 4    | 9      | 2.000         | 1    | 10     | 2.000         | 2    | 9      | 2.000         |
| Dizziness           |      |        |               |      |        |               |      |        |               |
| Low-expected        | 7    | 26     | 8.000         | 9    | 26     | 8.000         | 8    | 27     | 8.000         |
| High                | 3    | 10     | 2.000         | 1    | 10     | 2.000         | 2    | 9      | 2.000         |
| Increased perspiration |    |        |               |      |        |               |      |        |               |
| Low-expected        | 17   | 16     | 1.000         | 19   | 16     | 1.000         | 18   | 17     | 1.000         |
| High                | 6    | 7      | 5.000         | 4    | 7      | 5.000         | 5    | 6      | 5.000         |
| Itching             | 0.565| 1.000  | 1.000         |      |        |               |      |        |               |
| Low-expected        | 2    | 31     | 3.000         | 3    | 32     | 3.000         | 3    | 32     | 3.000         |
| High                | 2    | 11     | 1.000         | 1    | 10     | 1.000         | 1    | 10     | 1.000         |
| Headache            | 0.512| 1.000  | 0.169         |      |        |               |      |        |               |
| Low-expected        | 13   | 20     | 1.000         | 15   | 20     | 1.000         | 13   | 22     | 1.000         |
| High                | 7    | 6      | 7.000         | 5    | 6      | 7.000         | 7    | 4      | 7.000         |
| Tremor              | 0.565| 0.238  | 1.000         |      |        |               |      |        |               |
| Low-expected        | 2    | 31     | 2.000         | 2    | 33     | 2.000         | 3    | 32     | 3.000         |
| High                | 2    | 11     | 1.000         | 2    | 9      | 1.000         | 1    | 10     | 1.000         |
| Blurred vision      | 0.410| 1.000  | 0.421         |      |        |               |      |        |               |
| Low-expected        | 8    | 25     | 8.000         | 7    | 28     | 8.000         | 8    | 27     | 8.000         |
| High                | 1    | 12     | 1.000         | 2    | 9      | 1.000         | 1    | 10     | 1.000         |
| Difficulty sleeping | 1.000| 0.619  | 0.619         |      |        |               |      |        |               |
| Low-expected        | 4    | 29     | 4.000         | 4    | 31     | 4.000         | 4    | 31     | 4.000         |
| High                | 2    | 11     | 2.000         | 2    | 9      | 2.000         | 2    | 9      | 2.000         |
| Sleeping too much   | 1.000| 0.296  | 1.000         |      |        |               |      |        |               |
| Low-expected        | 13   | 20     | 1.000         | 12   | 23     | 1.000         | 14   | 21     | 1.000         |
| High                | 5    | 8      | 4.000         | 6    | 5      | 4.000         | 4    | 7      | 4.000         |
| Loss of sexual desire | 0.410| 0.664  | 1.000         |      |        |               |      |        |               |
| Low-expected        | 8    | 25     | 7.000         | 6    | 29     | 7.000         | 7    | 28     | 7.000         |
| High                | 1    | 12     | 2.000         | 3    | 8      | 2.000         | 2    | 9      | 2.000         |
| Poor concentration  | 0.461| 1.000  | 0.242         |      |        |               |      |        |               |
| Low-expected        | 10   | 23     | 11.000        | 9    | 26     | 11.000        | 11   | 24     | 11.000        |
| High                | 2    | 11     | 1.000         | 3    | 8      | 1.000         | 1    | 10     | 1.000         |

Fisher’s exact test applied for the comparisons. CITA: citalopram, NDCITA: n-desmethylcitalopram, CITA & NDCITA: citalopram and n-desmethylcitalopram, R: reporter, NR: nonreporter
rum CITA concentrations was 30 ng/mL after day 7. In contrast to previous results, in this study, only 1 patient had a serum CITA concentration below 50 ng/mL (42 ng/mL), and we did not observe any relationship between the efficacy and serum CITA concentrations according to the patient groups with low (<86.0 ng/mL), expected (86.0–136.0 ng/mL), and high (>136.0 ng/mL) CITA concentrations at the 4th week. We measured relatively higher median serum CITA concentrations (101 ng/mL) compared to earlier reports than in the reports of previous results.11,12,15-17 The difference in the serum CITA concentrations of this study might be explained in part by the sampling time for citalopram, taking comedication, and CYP2C19 polymorphisms. Because citalopram is extensively metabolized by CYP2C19,18 CYP2C19 polymorphisms, and the use of CYP2C19 inhibitors, especially proton pump inhibitors could increase the citalopram concentrations.19,20

This is one of the first studies to exhibit a potential relationship between the efficacy of CITA and serum NDCITA concentrations. We found a more significant reduction in the relationship between the efficacy of CITA and serum NDCITA concentrations and the time of the blood sampling. The lack of CYP2C19 genotyping is a major limitation of the study. The number of patients was relatively small for examining the relationship between serum concentrations and efficacy and tolerability. In addition, the blood samples for the measurements of serum concentrations were drawn at steady-state but did not represent trough concentrations.

Despite these limitations, the present study showed that serum concentrations of NDCITA have an impact on the efficacy but not on the tolerability of CITA. In addition, serum concentrations of CITA were not associated with either efficacy or with the tolerability of the drug. The results of this study provide the first evidence for the potential contribution of NDCITA to the antidepressant effect of CITA at higher serum concentrations of the drug. The studies in larger clinical samples, at multiple dose levels, and also including trough serum concentrations of CITA and NDCITA are required to confirm whether the impact of serum CITA and NDCITA concentrations on the efficacy and tolerability of CITA.

Acknowledgements

This study was supported by grants from the Scientific Research Projects of Gazi University (Project No: 01/2004–44).

REFERENCES

1. Trivedi MH. Major depressive disorder: remission of associated symptoms. J Clin Psychiatry 2006;67(Suppl 6):27-32.
2. Karlsson H. Remission in depression—is it a realistic goal? Nord J Psychiatry 2008;62:421-422.
3. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649-659.
4. Hiemke C. Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Eur Arch Psychiatry Clin Neurosci 2008;258(Suppl 1):21-27.
5. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011;44:195-235.
6. Muller MJ, Dragicevic A, Fric M, Gaertner I, Grasmader K, Hartter S, et al. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmaceutio 2003;36:98-104.
7. Wille SM, Cooreman SG, Neels HM, Lambert WE. Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci 2008;45:25-89.
8. Bechlhibnyk-Butler K, Aleksić I, Kennedy SH. Citalopram—a review of pharmacological and clinical effects. J Psychiatry Neurosci 2000;25:241-254.
9. Tatsunami M, Grosshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340:249-258.
10. Bjerkenstedt L, Flyckt L, Overo KF, Lingiserde O. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels. Eur J Clin Pharmacol 1985;28:553-557.
11. Ostad Haji E, Tadic A, Wagner S, Dragicevic A, Muller MJ, Boland K, et al. Early improvement and serum concentrations of citalopram to predict antidepressant drug response of patients with major depression. Pharmacopsychiatry 2013;46:261-266.
12. Ostad Haji E, Tadic A, Wagner S, Dragicevic A, Muller MJ, Boland K, et al. Association between citalopram serum levels and clinical improvement of patients with major depression. J Clin Psychopharmacol 2011;31:281-286.
13. Ozbeş G, Yucel B, Taycan SE, Kan D, Bodur NE, Arslan T, et al. ABCB1 C3435T polymorphism is associated with susceptibility to major depression.
pression, but not with a clinical response to citalopram in a Turkish population. Pharmacol Rep 2014;66:235-238.

14. Duverneuil C, de la Grandmaison GL, de Mazancourt P, Alvarez JC. A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs. Ther Drug Monit 2003;25:565-573.

15. Charlier C, Pinto E, Anseau M, Plomteux G. Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol 2000;15:453-459.

16. Reis M, Aamo T, Spigset O, Ahlner J. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 2009;31:42-56.

17. Reis M, Olsson G, Carlsson B, Lundmark J, Dahl ML, Walinder J, et al. Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting. J Clin Psychopharmacol 2002;22:406-413.

18. Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther 2015;98:127-134.

19. Wenzel-Seifert K, Brandl R, Hiemke C, Haen E. Influence of concomitant medications on the total clearance and the risk for supra-therapeutic plasma concentrations of Citalopram. A population-based cohort study. Pharmacopsychiatry 2014;47:239-244.

20. Klieber M, Oberacher H, Hofstaetter S, Beer B, Neururer M, Amann A, et al. CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine. J Pharmacol Exp Ther 2015;354:426-430.

21. Deupree JD, Montgomery MD, Bylund DB. Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram. Eur J Pharmacol 2007;576:55-60.

22. Hiemke C. Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol 2008;64:159-166.